Warner Chilcott files patent suit over Loestrin 24 Fe
Warner Chilcott says that it has filed suit against Watson Laboratories and Watson Pharmaceuticals in the US District Court for the District of New Jersey alleging infringement of its US patent that protects Loestrin (norethindrone/ethinyl estradiol) 24 Fe.
The law suit is in response to an Abbreviated New Drug Application filed by Watson with the Food and Drug Administration regarding Watson's intent to market a generic version of Loestrin 24 Fe prior to the expiration of Warner Chilcott's patent No 5,552,394.
The company says it has full confidence in, and will continue to vigorously defend and enforce, its intellectual property rights protecting Loestrin 24 Fe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze